ADC Therapeutics SA
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 7 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
ADC Therapeutics has 4 disclosed suppliers and 7 disclosed customers in SEC filings.
ADC Therapeutics SA
1.52
NoteDecember 31, 2024 Accounts receivable, net $ 1,658 $ 1,792 Other current liabilities 9,020 15,697 $ 10,678 $ 17,489 Customers from which we derive more than 10% of our total product revenues are as follows
| Years ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| AmerisourceBergen Corporation (1) | 39% | 35% |
basisADCT FY2024 revenue $71M
ADCT 10-Kaccession 0001628280-26-016491
NoteDecember 31, 2024 Accounts receivable, net $ 1,658 $ 1,792 Other current liabilities 9,020 15,697 $ 10,678 $ 17,489 Customers from which we derive more than 10% of our total product revenues are as follows
| Years ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| McKesson | 39% | 41% |
basisADCT FY2024 revenue $71M
ADCT 10-Kaccession 0001628280-26-016491
NoteDecember 31, 2024 Accounts receivable, net $ 1,658 $ 1,792 Other current liabilities 9,020 15,697 $ 10,678 $ 17,489 Customers from which we derive more than 10% of our total product revenues are as follows
| Years ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cardinal Health | 22% | 24% |
basisADCT FY2024 revenue $71M
ADCT 10-Kaccession 0001628280-26-016491
SentenceUnder the terms of the agreement, MedImmune has granted us an exclusive, worldwide license under certain patent rights and related know-how to make, have made, use, sell, offer for sale and import product candidates in the field of human therapeutics and diagnostics that consist of (i) PBD-based molecules directly conjugated to an antibody (i.e., ADCs with a PBD-based warhead) that specifically bind to up to 11 approved targets ("ADC Targets"), and (ii) PBD-based molecules conjugated to a non-antibody (i.e., targeting-moiety conjugates with a PBD-based warhead) that specifically bind to up to ten approved targets ("XDC Targets").
ADCT 10-Kaccession 0001628280-26-016491
SentenceIn 2011, we (then operating under the name ADCT Sàrl) entered into a license and collaboration agreement with Spirogen (since renamed ADC Products UK Ltd.), pursuant to which Spirogen granted us access to its next-generation PBD-based warhead and linker technology.
ADCT 10-Kaccession 0001628280-26-016491
SentenceThe Company agreed to supply product to Overland ADCT BioPharma for its drug development and commercialization under a supply agreement entered into between the parties.
ADCT 10-Kaccession 0001628280-26-016491
SentenceWe are required to use diligent efforts to manufacture and supply to Overland ADCT BioPharma (at our manufacturing cost), and Overland ADCT BioPharma must purchase from us, all of Overland ADCT BioPharma's requirements of the Licensed Products for its development and commercialization activities.
ADCT 10-Kaccession 0001628280-26-016491
SentenceIn March 2025, the Company recognized $5.0 million in license revenue in connection with a milestone due upon ZYNLONTA's conditional approval by Health Canada for the treatment of relapsed or refractory DLBCL after two or more lines of systemic therapy, which was paid to us by Sobi in the second quarter of 2025.
ADCT 10-Kaccession 0001628280-26-016491
SentenceIn January 2022, we entered into a license agreement with TPC, to develop and commercialize ZYNLONTA in Japan, pursuant to which we granted TPC an exclusive license under all applicable patents and know-how relating to ZYNLONTA in order to use, sell, offer for sale, import and commercialize ZYNLONTA for all cancer indications in Japan.
ADCT 10-Kaccession 0001628280-26-016491
Expected move
No implied move.